DOCSLIB.ORG

Reference Standards Tables New Reference Standards Now Available

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Reference Standards Tables New Reference Standards Now Available Reference Standards Tables Below are several tables with the latest Reference Standard information including out-of-stock items now available; new Reference Standards released in the last month; backordered items with estimated availability dates; items with lots that are no longer valid (or soon will be invalid); and items with new lots since the last newsletter. USP strongly suggest downloading the FREE Reference Standards and Resources APP to easily track and receive notifications and alerts for the Reference Standards of interest to you. Please contact your USP Customer Service Representative to place an order at +1-301-881-0666 or 1-800-227-8772. European customers can call 00-800-4875-5555. You can also order online at http://www.usp.org/products New Reference Standards Now Available Items With Replacement Lots Backorder Availability Report As of July 31, 2018 Previously Out-of-Stock Items Now Available No Longer Valid as of August 2018 New Reference Standards Now Available Catalog # Description Current Lot Start Date# Price 1013807 Alosetron Hydrochloride (200 mg) (2,3,4,5- F074D0 18-Jul-18 $930.00 Tetrahydro-5-methyl-2-[(5-methylimidazol- 4-yl)methyl]-1H-pyrido[4,3-b]indol-1-one hydrochloride) 1191011 Dicyclomine Related Compound A (40 mg) F090G0 16-Jul-18 $730.00 ([1,1'-Bi(cyclohexane)]-1-carboxylic acid) 1606140 Rotigotine Related Compound G (25 mg) F086G0 5-Jul-18 $895.00 ((S)-6-{Bis[2-(thiophen-2-yl)ethyl]amino}- 5,6,7,8-tetrahydronaphthalen-1-ol hydrochloride) 1142195 Cobamamide (3 x 100 mg) (5,6- F058G0 5-Jul-18 $230.00 Dimethylbenzimidazolyl-Co-5'- deoxyadenosylcobamide) 1548350 Potassium Nitrate Melting Point Standard (1 F06880 30-Jul-18 $140.00 g) (Potassium Nitrate) 1202253 Rotigotine Related Compound K (25 mg) F086J0 16-Jul-18 $495.00 (7,8-Dihydronaphthalen-1-ol) 1598733 p-Ranolazine (25 mg) (N-(2,6- F092J0 5-Jul-18 $400.00 Dimethylphenyl)-2-{4-[2-hydroxy-3-(4- methoxyphenoxy)propyl]piperazin-1- yl}acetamide) 1165667 Deferasirox System Suitability Mixture (20 F09480 24-Jul-18 $730.00 mg) (A mixture containing Deferasirox, Benzoxazinone analog, Deferasirox ethyl ester, Deferasirox 1,2-isomer, Deferasirox 1,3-isomer and Salicylimide) 1554749 Prazosin Related Compound D (25 mg) F091E0 16-Jul-18 $730.00 (Furan-2-yl(piperazin-1-yl)methanone) 1553848 Pramipexole Related Compound G (25 mg) F09180 16-Jul-18 $895 ((6S,7S)-2-Amino-6-(propylamino)-4,5,6,7- tetrahydrobenzothiazol-7-ol) Return To The Top Items with Replacement Lots Catalog # Description Current Previous Lot Price Lot (Valid Use Date) 1012178 5'-Adenylic Acid (500 mg) R08510 F0J204 (30-Jun-19) $225.00 1035005 Anethole (4 x 0.5 mL) R090M0 G0L346 (31-May-19) $255.00 1098515 Celecoxib Related Compound A (10 mg) R091W0 R008U0 (30-Jun-19) $730.00 (4-[5-(3-methylphenyl)-3- (trifluoromethyl)-1H-pyrazol-1- yl]benzenesulfonamide) 1102974 Cetrimonium Bromide (1 g) R093Y0 F0F316 (31-Jul-19) $255.00 1106001 Chlorambucil (125 mg) R098C0 G (31-May-19) $185.00 1134404 Clavam-2-carboxylate Potassium (2 mg) L2L187 L1L187 (30-Jun-19) $805.00 1140305 Clonazepam CIV (200 mg) R074V0 R008P0 (30-Jun-19) $305.00 1171003 Denatonium Benzoate (200 mg) R086X0 R020M0 (31-Jul-19) $230.00 1179628 Dextran 1 (50 mg) R09240 F0D297 (30-Apr-19) $275.00 1235933 Entacapone (200 mg) R040K0 F1L210 (31-Jul-19) $440.00 1261004 Ethionamide (200 mg) R096T0 H0B148 (31-Jul-19) $230.00 1287518 Gadodiamide Related Compound A (25 R04030 F (31-Jul-19) $730.00 mg) (gadolinium sodium diethylenetriamine pentaacetic acid monomethylamide) 1315001 Hydrocodone Bitartrate CII (100 mg) N2I034 N1I034 (31-Jul-19) $305.00 1356009 Ketamine Hydrochloride CIII (250 mg) R083G0 I0J272 (31-Jul-19) $305.00 1286209 Mafenide Related Compound A (50 mg) R084T0 G0C351 (31-May- $805.00 (4-Formylbenzenesulfonamide) 19) 1398009 Methadone Hydrochloride CII (200 mg) R082A0 J0L220 (31-Jul-19) $305.00 1479315 Oseltamivir Related Compound A (10 mg) R092M0 F0J053 (31-Dec-18) $805.00 ((3S,4R,5S)-ethyl 4-acetamido-5-amino-2- azido-3-(pentan-3- yloxy)cyclohexanecarboxylate) 1481204 Oxaliplatin (125 mg) R09690 R006C0 (30-Jun-19) $1,180.00 1524001 Phenobarbital CIV (200 mg) R090B0 K0H134 (30-Jun-19) $305.00 1559505 Prednisone Tablets (30 tablets) R072M0 R05991 (30-Sep-18) $285.00 1598020 Rabeprazole Related Compound A (25 mg) R023B0 F0L165 (31-Jul-19) $805.00 (1-(1H-Benzimidazol-2-yl)-3-methyl-4-oxo- 1,4-dihydropyridine-2-carboxylate, sodium salt) 1613655 Sodium Bicarbonate (3 g) R090L0 G0M440 (31-Jul-19) $230.00 1614363 Sodium Lauryl Sulfate (1 g) R100F0 R070F1 (30-Jun-19) $230.00 1612719 Tenivastatin Calcium (2 x 15 mg) (Calcium R09920 F011Q0 (30-Oct-17) $715.00 (3R,5R)-7-{(1S,2S,6R,8S,8aR)-8-[(2,2- dimethylbutanoyl)oxy]-2,6-dimethyl- 1,2,6,7,8,8a-hexahydronaphthalen-1-yl}- 3,5-dihydroxyheptanoate (1:2) monohydrate) 1649007 Testosterone Propionate CIII (200 mg) R07570 M0J023 (31-Jul-19) $305.00 Return To The Top Backorder Availability As of July 31st Catalog # Description Estimated Availability 1011878 Adrenalone Hydrochloride (25 mg) (3',4'-Dihydroxy-2- Q3 (methylamino)acetophenone hydrochloride) 1012780 Alendronate Sodium (200 mg) Q3 1021000 Aminocaproic Acid (200 mg) Q3 1032007 Amphotericin B (125 mg) (INTERNATIONAL COLD CHAIN SHIPMENT Q3 REQUIRED) 1042780 Artemether (100 mg) Q3 1045009 Atropine Sulfate (500 mg) Q3 1051001 Benzalkonium Chloride (5 mL of approx. 10% aqueous solution) Q4 1071381 Biochanin A (20 mg) Q3 1086006 Caffeine Melting Point Standard (1 g) (Approximately 236 degrees) Q3 1086866 Calcium (-)-Hydroxycitrate (150 mg) Q3 1098130 Ceftazidime Pentahydrate (300 mg) Q3 1134379 Clarithromycin (100 mg) Q3 1151866 Curcuminoids (300 mg) Q4 1157002 Cyclophosphamide (500 mg) Q3 1158650 Cyclosporine Resolution Mixture (25 mg) (This material is an approximate Q3 100:1 (w/w) mixture of cyclosporine and cyclosporine U) 1185008 Diazepam CIV (100 mg) Q3 1225281 Dorzolamide Hydrochloride (200 mg) Q3 1228009 Drometrizole (25 mg) (2-(2H-Benzotriazol-2-yl)-p-cresol) Q3 1237509 Epitetracycline Hydrochloride (250 mg) Q3 1237600 Epoprostenol Sodium (100 mg) (COLD SHIPMENT REQUIRED) Q4 1241550 Ergotaminine (100 mg) Q4 1257018 Ethambutol Related Compound A (15 mg) ((2R,2'S)-2,2'-[ethane-1,2- Q3 diylbis(azanediyl)]dibutan-1-ol) 1274607 Flunixin Meglumine (300 mg) Q4 1279826 Fluoxetine Related Compound B (5 mL of a 0.01N HCl Solution, approx. 2 Q3 mg/mL) (N-Methyl-3-phenylpropylamine) 1282004 Fluphenazine Hydrochloride (125 mg) Q4 1291446 Ginger Constituent Mixture (0.2 mg) (6-gingerol and 6-shogaol) Q3 1291559 Ginkgo Terpene Lactones (50 mg) Q3 1325005 Hydroxyamphetamine Hydrobromide (200 mg) TBD 1330005 Hypromellose (250 mg) (Hydroxypropyl Methylcellulose) Q3 1358503 Leuprolide Acetate (200 mg) (INTERNATIONAL COLD CHAIN SHIPMENT Q3 REQUIRED) 1361010 Levodopa Related Compound A (50 mg) ((3-(2,4,5-Trihydroxyphenyl)-L- Q3 alanine) or (3-(3,4,6-Trihydroxyphenyl)alanine)) 1365021 Levothyroxine for Peak Identification (15 mg) (levothyroxine sodium spiked Q4 with liothyronine, triiodothyroacetic acid, tetraiodothyroacetic acid) 1375502 Mebendazole (200 mg) Q3 1377803 Meclofenamate Sodium (500 mg) Q4 1381119 Menaquinone-7 (3 x 50 mg) (Vitamin K2) Q4 1395204 Metacresol (1 mL) Q3 1422001 Methsuximide (500 mg) Q3 1424051 Methyl Acetate (1.2 mL/ampule; 3 ampules) Q3 1430327 Methyl Linoleate (5 x 50 mg) Q3 1444235 Mirtazapine Related Compound B (25 mg) (1,2,3,4,10,14b-Hexahydro-2- Q3 methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine 2-oxide monohydrate) 1457469 Naratriptan Hydrochloride (125 mg) Q3 1500003 Paromomycin Sulfate (125 mg) Q3 1500400 Parthenolide (25 mg) Q3 1530004 Phentolamine Mesylate (200 mg) Q3 1543200 Piperine (20 mg) Q3 1561507 Primaquine Phosphate (200 mg) Q4 1565009 Procarbazine Hydrochloride (200 mg) Q3 1578554 Prostaglandin B1 (25 mg) ((13E,15S)-15-Hydroxy-9-oxoprosta-8(12),13-dien-1- Q3 oic Acid) 1600121 Rebaudioside A (500 mg) Q4 1601703 Residual Solvent Class 2 - N-Methylpyrrolidone (1.2 mL/ampule; 3 ampules) Q3 1605512 Ropivacaine Related Compound A (25 mg) (2,6-dimethylaniline hydrochloride) Q3 1612007 Sennosides (500 mg) Q4 1612630 Silybin (50 mg) Q4 1617420 Sotalol Related Compound B (50 mg) (N-(4- Q3 Formylphenyl)methanesulfonamide) 1642100 Sulisobenzone (500 mg) Q3 1667643 Tigecycline (300 mg) (INTERNATIONAL COLD CHAIN SHIPMENT REQUIRED) Q4 1675007 Triacetin (1 g) Q3 1711100 Vasopressin (1.70 mg) (8-L-arginine vasopressin) (COLD SHIPMENT REQUIRED) Q4 1713004 Vinblastine Sulfate (50 mg) Q4 1724441 Ziprasidone Related Compound C (10 mg) (5,5'-Bis(2-(4-(benzo[d]isothiazol-3- Q3 yl)piperazin-1-yl)ethyl)-6,6'-dichloro-3-hydroxy-3,3'-biindoline-2,2'-dione) *Dates are targets and may change at any time. Q1January—March, Q2 April –June, Q3- July – September, Q4- October –December Return To The Top Previously Out of Stock Items Now Available Catalog # Description and Package Size Lot Price 1236700 (-)-Epigallocatechin-3-O-gallate (20 mg) R088T0 $200.00 1083008 2-tert-Butyl-4-hydroxyanisole (200 mg) R07460 $255.00 1012178 5'-Adenylic Acid (500 mg) R08510 $225.00 1011878 Adrenalone Hydrochloride (25 mg) (3',4'-Dihydroxy-2- F032A0 $805.00 (methylamino)acetophenone hydrochloride) 1013807 Alosetron Hydrochloride (200 mg) (2,3,4,5-Tetrahydro-5- F074D0 $930.00 methyl-2-[(5-methylimidazol-4-yl)methyl]-1H-pyrido[4,3- b]indol-1-one hydrochloride 1035005 Anethole (4 x 0.5 mL) R090M0 $255.00 1045009 Atropine Sulfate (500 mg) R01050 $230.00 1050905 Benzaldehyde (3 X 1 mL) (List Chemical) R079U0 $230.00 1078201 Budesonide (200 mg) R079R0 $230.00 1078245 Budesonide Related Compound E (25 mg) (16alpha,17- R07730 $730.00 [butylidenebis(oxy)]-11Beta,21-dihydroxypregna-1,4,14-
Load more

Recommended publications
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr
    Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Crizotinib (PF-02341066) 1 4 55 Docetaxel 1 5 98 Anastrozole 1 6 25 Cladribine 1 7 23 Methotrexate 1 8 -187 Letrozole 1 9 65 Entecavir Hydrate 1 10 48 Roxadustat (FG-4592) 1 11 19 Imatinib Mesylate (STI571) 1 12 0 Sunitinib Malate 1 13 34 Vismodegib (GDC-0449) 1 14 64 Paclitaxel 1 15 89 Aprepitant 1 16 94 Decitabine 1 17 -79 Bendamustine HCl 1 18 19 Temozolomide 1 19 -111 Nepafenac 1 20 24 Nintedanib (BIBF 1120) 1 21 -43 Lapatinib (GW-572016) Ditosylate 1 22 88 Temsirolimus (CCI-779, NSC 683864) 1 23 96 Belinostat (PXD101) 1 24 46 Capecitabine 1 25 19 Bicalutamide 1 26 83 Dutasteride 1 27 68 Epirubicin HCl 1 28 -59 Tamoxifen 1 29 30 Rufinamide 1 30 96 Afatinib (BIBW2992) 1 31 -54 Lenalidomide (CC-5013) 1 32 19 Vorinostat (SAHA, MK0683) 1 33 38 Rucaparib (AG-014699,PF-01367338) phosphate1 34 14 Lenvatinib (E7080) 1 35 80 Fulvestrant 1 36 76 Melatonin 1 37 15 Etoposide 1 38 -69 Vincristine sulfate 1 39 61 Posaconazole 1 40 97 Bortezomib (PS-341) 1 41 71 Panobinostat (LBH589) 1 42 41 Entinostat (MS-275) 1 43 26 Cabozantinib (XL184, BMS-907351) 1 44 79 Valproic acid sodium salt (Sodium valproate) 1 45 7 Raltitrexed 1 46 39 Bisoprolol fumarate 1 47 -23 Raloxifene HCl 1 48 97 Agomelatine 1 49 35 Prasugrel 1 50 -24 Bosutinib (SKI-606) 1 51 85 Nilotinib (AMN-107) 1 52 99 Enzastaurin (LY317615) 1 53 -12 Everolimus (RAD001) 1 54 94 Regorafenib (BAY 73-4506) 1 55 24 Thalidomide 1 56 40 Tivozanib (AV-951) 1 57 86 Fludarabine
    [Show full text]
  • WO 2014/153004 Al 25 September 2014 (25.09.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2014/153004 Al 25 September 2014 (25.09.2014) P O P C T (51) International Patent Classification: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, A61L 27/58 (2006.01) A61L 27/52 (2006.01) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (21) International Application Number: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, PCT/US20 14/028622 SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (22) International Filing Date: TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, 14 March 2014 (14.03.2014) ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (26) Publication Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (30) Priority Data: UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, 61/785,477 14 March 2013 (14.03.2013) US TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (71) Applicant: MEDICUS BIOSCIENCES LLC [US/US]; MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, 2528 Qume Dr., Unit #1, San Jose, CA 95 13 1 (US).
    [Show full text]
  • The Organic Chemistry of Drug Synthesis
    The Organic Chemistry of Drug Synthesis VOLUME 2 DANIEL LEDNICER Mead Johnson and Company Evansville, Indiana LESTER A. MITSCHER The University of Kansas School of Pharmacy Department of Medicinal Chemistry Lawrence, Kansas A WILEY-INTERSCIENCE PUBLICATION JOHN WILEY AND SONS, New York • Chichester • Brisbane • Toronto Copyright © 1980 by John Wiley & Sons, Inc. All rights reserved. Published simultaneously in Canada. Reproduction or translation of any part of this work beyond that permitted by Sections 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc. Library of Congress Cataloging in Publication Data: Lednicer, Daniel, 1929- The organic chemistry of drug synthesis. "A Wiley-lnterscience publication." 1. Chemistry, Medical and pharmaceutical. 2. Drugs. 3. Chemistry, Organic. I. Mitscher, Lester A., joint author. II. Title. RS421 .L423 615M 91 76-28387 ISBN 0-471-04392-3 Printed in the United States of America 10 987654321 It is our pleasure again to dedicate a book to our helpmeets: Beryle and Betty. "Has it ever occurred to you that medicinal chemists are just like compulsive gamblers: the next compound will be the real winner." R. L. Clark at the 16th National Medicinal Chemistry Symposium, June, 1978. vii Preface The reception accorded "Organic Chemistry of Drug Synthesis11 seems to us to indicate widespread interest in the organic chemistry involved in the search for new pharmaceutical agents. We are only too aware of the fact that the book deals with a limited segment of the field; the earlier volume cannot be considered either comprehensive or completely up to date.
    [Show full text]
  • 3258 N:O 1179
    3258 N:o 1179 LIITE 1 BILAGA 1 LÄÄKELUETTELON AINEET ÄMNENA I LÄKEMEDELSFÖRTECKNINGEN Latinankielinen nimi Suomenkielinen nimi Ruotsinkielinen nimi Englanninkielinen nimi Latinskt namn Finskt namn Svenskt namn Engelskt namn Abacavirum Abakaviiri Abakavir Abacavir Abciximabum Absiksimabi Absiximab Abciximab Acamprosatum Akamprosaatti Acamprosat Acamprosate Acarbosum Akarboosi Akarbos Acarbose Acebutololum Asebutololi Acebutolol Acebutolol Aceclofenacum Aseklofenaakki Aceklofenak Aceclofenac Acediasulfonum natricum Asediasulfoninatrium Acediasulfonnatrium Acediasulfone sodium Acepromazinum Asepromatsiini Acepromazin Acepromazine Acetarsolum Asetarsoli Acetarsol Acetarsol Acetazolamidum Asetatsoliamidi Acetazolamid Acetazolamide Acetohexamidum Asetoheksamidi Acetohexamid Acetohexamide Acetophenazinum Asetofenatsiini Acetofenazin Acetophenazine Acetphenolisatinum Asetofenoli-isatiini Acetfenolisatin Acetphenolisatin Acetylcholini chloridum Asetyylikoliinikloridi Acetylkolinklorid Acetylcholine chloride Acetylcholinum Asetyylikoliini Acetylkolin Acetylcholini Acetylcysteinum Asetyylikysteiini Acetylcystein Acetylcysteine Acetyldigitoxinum Asetyylidigitoksiini Acetyldigitoxin Acetyldigitoxin Acetyldigoxinum Asetyylidigoksiini Acetyldigoxin Acetyldigoxin Acetylisovaleryltylosini Asetyyli-isovaleryyli- Acetylisovaleryl- Acetylisovaleryltylosine tartras tylosiinitartraatti tylosintartrat tartrate Aciclovirum Asikloviiri Aciklovir Aciclovir Acidum acetylsalicylicum Asetyylisalisyylihappo Acetylsalicylsyra Acetylsalicylic acid Acidum alendronicum
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,026,285 B2 Bezwada (45) Date of Patent: Sep
    US008O26285B2 (12) United States Patent (10) Patent No.: US 8,026,285 B2 BeZWada (45) Date of Patent: Sep. 27, 2011 (54) CONTROL RELEASE OF BIOLOGICALLY 6,955,827 B2 10/2005 Barabolak ACTIVE COMPOUNDS FROM 2002/0028229 A1 3/2002 Lezdey 2002fO169275 A1 11/2002 Matsuda MULT-ARMED OLGOMERS 2003/O158598 A1 8, 2003 Ashton et al. 2003/0216307 A1 11/2003 Kohn (75) Inventor: Rao S. Bezwada, Hillsborough, NJ (US) 2003/0232091 A1 12/2003 Shefer 2004/0096476 A1 5, 2004 Uhrich (73) Assignee: Bezwada Biomedical, LLC, 2004/01 17007 A1 6/2004 Whitbourne 2004/O185250 A1 9, 2004 John Hillsborough, NJ (US) 2005/0048121 A1 3, 2005 East 2005/OO74493 A1 4/2005 Mehta (*) Notice: Subject to any disclaimer, the term of this 2005/OO953OO A1 5/2005 Wynn patent is extended or adjusted under 35 2005, 0112171 A1 5/2005 Tang U.S.C. 154(b) by 423 days. 2005/O152958 A1 7/2005 Cordes 2005/0238689 A1 10/2005 Carpenter 2006, OO13851 A1 1/2006 Giroux (21) Appl. No.: 12/203,761 2006/0091034 A1 5, 2006 Scalzo 2006/0172983 A1 8, 2006 Bezwada (22) Filed: Sep. 3, 2008 2006,0188547 A1 8, 2006 Bezwada 2007,025 1831 A1 11/2007 Kaczur (65) Prior Publication Data FOREIGN PATENT DOCUMENTS US 2009/0076174 A1 Mar. 19, 2009 EP OO99.177 1, 1984 EP 146.0089 9, 2004 Related U.S. Application Data WO WO9638528 12/1996 WO WO 2004/008101 1, 2004 (60) Provisional application No. 60/969,787, filed on Sep. WO WO 2006/052790 5, 2006 4, 2007.
    [Show full text]
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule
    Harmonized Tariff Schedule of the United States (2020) Revision 8 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 8 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Compendial Deferrals for USP41-NF36 1S
    Compendial Deferrals for USP41-NF36 1S Category Monograph Title Monograph Section Scientific Liaison {Emollient} Sodium Lauroyl Sarcosinate, {Emulsifying Agent} Sodium Lauroyl Revision USP AND NF EXCIPIENTS, LISTED BY CATEGORY PF 42(2) Pg. ONLINE Sarcosinate, {Chaotropic Agent} Hong Wang Introduction, 1. INTRODUCTION, 2. GENERAL QUALITY TESTS FOR INHALATION DRUG <5> INHALATION AND NASAL DRUG PRODUCTS GENERAL INFORMATION AND PRODUCTS, 3. GENERAL QUALITY TESTS FOR NASAL DRUG PRODUCTS, 4. Revision PRODUCT QUALITY TESTS PF 43(1) Pg. ONLINE DESCRIPTION OF PRODUCT QUALITY TESTS Kahkashan Zaidi Bendamustine Hydrochloride, Ropivacaine, Bortezomib, Sodium Lauroyl Sarcosinate, Epinastine Hydrochloride, Imipramine Hydrochloride, Carglumic Acid, Iloperidone, Benzphetamine Hydrochloride, Deferasirox, Eletriptan Hydrobromide, Milnacipran New DESCRIPTION AND SOLUBILITY PF 43(1) Pg. ONLINE Hydrochloride, Nebivolol Hydrochloride Feiwen Mao Title, INTRODUCTION/Introduction, PROCEDURE/Identification, PROCEDURE/Enumeration, PERFORMANCE TESTS/, CONTAMINANTS/Introduction, CONTAMINANTS/Listeria, ADDITIONAL REQUIREMENTS/Storage, ADDITIONAL New <64> PROBIOTIC TESTS - GENERAL PF 43(2) Pg. ONLINE REQUIREMENTS/Labeling, ??UNKNOWN??/Introduction Seong Jae Yoo Title, Introduction, INTRODUCTION, CHARACTERISTICS, IDENTIFICATION, TEST PROCEDURES, BIOLOGICAL TESTS, PHYSICOCHEMICAL TESTS, FUNCTIONALITY New <381> ELASTOMERIC CLOSURES FOR INJECTIONS PF 43(3) Pg. ONLINE TESTS, 1. INTRODUCTION, 2. SCOPE, 3. SPECIFICATIONS, 4. TEST METHODS Desmond Hunt Title, 1. INTRODUCTION,
    [Show full text]
  • Vr Meds Ex01 3B 0825S Coding Manual Supplement Page 1
    vr_meds_ex01_3b_0825s Coding Manual Supplement MEDNAME OTHER_CODE ATC_CODE SYSTEM THER_GP PHRM_GP CHEM_GP SODIUM FLUORIDE A12CD01 A01AA01 A A01 A01A A01AA SODIUM MONOFLUOROPHOSPHATE A12CD02 A01AA02 A A01 A01A A01AA HYDROGEN PEROXIDE D08AX01 A01AB02 A A01 A01A A01AB HYDROGEN PEROXIDE S02AA06 A01AB02 A A01 A01A A01AB CHLORHEXIDINE B05CA02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D08AC02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D09AA12 A01AB03 A A01 A01A A01AB CHLORHEXIDINE R02AA05 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S01AX09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S02AA09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S03AA04 A01AB03 A A01 A01A A01AB AMPHOTERICIN B A07AA07 A01AB04 A A01 A01A A01AB AMPHOTERICIN B G01AA03 A01AB04 A A01 A01A A01AB AMPHOTERICIN B J02AA01 A01AB04 A A01 A01A A01AB POLYNOXYLIN D01AE05 A01AB05 A A01 A01A A01AB OXYQUINOLINE D08AH03 A01AB07 A A01 A01A A01AB OXYQUINOLINE G01AC30 A01AB07 A A01 A01A A01AB OXYQUINOLINE R02AA14 A01AB07 A A01 A01A A01AB NEOMYCIN A07AA01 A01AB08 A A01 A01A A01AB NEOMYCIN B05CA09 A01AB08 A A01 A01A A01AB NEOMYCIN D06AX04 A01AB08 A A01 A01A A01AB NEOMYCIN J01GB05 A01AB08 A A01 A01A A01AB NEOMYCIN R02AB01 A01AB08 A A01 A01A A01AB NEOMYCIN S01AA03 A01AB08 A A01 A01A A01AB NEOMYCIN S02AA07 A01AB08 A A01 A01A A01AB NEOMYCIN S03AA01 A01AB08 A A01 A01A A01AB MICONAZOLE A07AC01 A01AB09 A A01 A01A A01AB MICONAZOLE D01AC02 A01AB09 A A01 A01A A01AB MICONAZOLE G01AF04 A01AB09 A A01 A01A A01AB MICONAZOLE J02AB01 A01AB09 A A01 A01A A01AB MICONAZOLE S02AA13 A01AB09 A A01 A01A A01AB NATAMYCIN A07AA03 A01AB10 A A01
    [Show full text]
  • Alphabetical Listing of ATC Drugs & Codes
    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
    [Show full text]
  • Method for the Enzymatic Kinetic Resolution of Acyloxyalkyl Thiocarbonates Used for the Synthesis of Acyloxyalkyl Carbamates
    (19) TZZ Z_¥_T (11) EP 2 250 143 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07B 57/00 (2006.01) C07C 269/04 (2006.01) 20.04.2016 Bulletin 2016/16 C07C 329/06 (2006.01) C07D 207/46 (2006.01) C12P 41/00 (2006.01) C07C 271/22 (2006.01) (2006.01) (2006.01) (21) Application number: 09704177.6 A61K 31/325 C12P 11/00 (22) Date of filing: 23.01.2009 (86) International application number: PCT/US2009/031873 (87) International publication number: WO 2009/094569 (30.07.2009 Gazette 2009/31) (54) METHOD FOR THE ENZYMATIC KINETIC RESOLUTION OF ACYLOXYALKYL THIOCARBONATES USED FOR THE SYNTHESIS OF ACYLOXYALKYL CARBAMATES VERFAHREN ZUR ENZYMATISCHEN KINETISCHEN RACEMATSPALTUNG VON FÜR DIE SYNTHESE VON ACYLOXYALKYLCARBAMATEN VERWENDETEN ACYLOXYALKYLTHIOCARBONATEN RESOLUTION CINETIQUE ENZYMATIQUE DE THIOCARBONATES D’ACYLOXYALKYLE UTILISES DANS LA SYNTHESE DE CARBAMATES D’ACYLOXYALKYLE (84) Designated Contracting States: • PENG, Ge AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Mountain View HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL California 94040 (US) PT RO SE SI SK TR • RAILLARD, Stephen, P. Mountain View, California 94040 (US) (30) Priority: 25.01.2008 US 23813 P 25.01.2008 US 23808 P (74) Representative: Wytenburg, Wilhelmus Johannes 11.12.2008 US 121859 P et al Mewburn Ellis LLP (43) Date of publication of application: City Tower 17.11.2010 Bulletin 2010/46 40 Basinghall Street London EC2V 5DE (GB) (73) Proprietor: XenoPort, Inc.
    [Show full text]